October 2016 Surety Medicine Teleconference:
VISION CONSERVATION AND READINESS PROGRAM: THE CMA PERSPECTIVE
Wednesday, 19 October 2016 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time. The topic for September will be “Vision Conservation and Readiness Program: The CMA Perspective.” The presenter will be a civilian optometrist of the Department of Defense Tri-Service Vision Program.
To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:
usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil
----------------------------------------------------------------------------------------------------------------
SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2017
|
DATE |
TOPIC (Dates and topics subject to revision) |
|
19 OCT 2016 |
Vision Conservation and Readiness Program: The CMA Perspective |
|
16 NOV 2016 |
Building and Sustaining a PRP Clinical Quality Assurance Program |
|
14 DEC 2016 |
The Ebola Epidemic: Lessons Learned on the Diagnosis, Evaluation
and Treatment of Ebola Infections Relevant to the CMA |
|
18 JAN 2017 |
Regulatory Policy Updates in Surety Medicine |
|
15 FEB 2017 |
Respirator Clearance and PPE Assessments: The Role of Use Testing |
|
15 MAR 2017 |
Peripheral Vascular Disease, DVT, and Anticoagulation—
Assessing PRP Suitability |
|
19 APR 2017 |
Abuse, Dependence and Substance Use Disorders:
DSM-IV-TR vs. DSM-5 |
|
17 MAY 2017 |
Screening for Active TB or LTBI: TB Skin tests vs. Alternatives |
|
21 JUN 2017 |
Heat Stress Prevention and Management Issues
in the Surety Environment |
|
19 JUL 2017 |
Syncopal Conditions: Impacts on PRP Reliability |
|
16 AUG 2017 |
Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA |
|
20 SEP 2017 |
Obstructive Sleep Apnea: Screening, Diagnosis,
Treatment and Compliance: The PRP Perspective |
ALERT: FDA Simplifies Rule for Anthrax PEP
FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS
The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax. The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.
Additional information is available from the FDA at:
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm
ALERT: Autoinjector Shelf Life Extension Program: Current Information
NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM
The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019. Complete FDA information related to the auto-injector shelf life extension program can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .
Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors.
_______________________________________________________________
SURETY MEDICINE REGULATIONS, GUIDANCE and USEFUL LINKS:
(Common Access Card or Army Knowledge Online account required for access to some documents)
AR 50-1 Biological Surety: http://armypubs.army.mil/epubs/pdf/r50_1.pdf
AR 50-5 Nuclear Surety: http://armypubs.army.mil/epubs/pdf/r50_5.pdf
AR 50-6 Chemical Surety: http://armypubs.army.mil/epubs/pdf/r50_6.pdf
AR 50-7 Army Reactor Program: http://armypubs.army.mil/epubs/pdf/r50_7.pdf
DA PAM 50-5 Nuclear Accident or Incident Response and Assistance Operations: http://armypubs.army.mil/epubs/pdf/p50_5.pdf
DA PAM 385-61 Toxic Chemical Agent Safety Standards: http://armypubs.army.mil/epubs/pdf/p385_61.pdf
Army Directive 2013-03 (Chemical Accident or Incident Response and Assistance): http://www.apd.army.mil/pdffiles/ad2013_03.pdf
TB MED 507 Heat Stress Control and Heat Casualty Management: http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed507.pdf
TB MED 590 Red Blood Cell Testing and Quality Assurance:
http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed590.pdf
Medical Command (MEDCOM) Regulation 40-55 Guidance on Occupational Health Practices for the Evaluation and Control of Occupational Exposures to Biological Select Agents and Toxins: https://www.us.army.mil/suite/doc/22064586
Additional Guidance Document Sources:
Army Publishing Directorate: http://armypubs.army.mil/index.html